As of November 10, 2026, Sutro Biopharma, Inc. is a publicly traded company (Nasdaq: STRO); its largest reported holder is Perceptive Advisors, with 7.9% on Schedule 13G/A of August 14, 2026, then BVF Partners (7.6%). The largest insider holding is William J. Newell, the chief executive and a director, with 409,056 shares (2.5% of shares outstanding), per Form 4 of March 7, 2025 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Sutro Biopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Sutro Biopharma, Inc. a real, registered company?
- Sutro Biopharma, Inc. files with the SEC under CIK 1382101 (its SEC filings).
- Its shares are listed under the ticker STRO on Nasdaq (SEC company record).
- business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Sutro Biopharma, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2025-09-29).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Coastlands Capital LP (filed 2026-11-09).
Who are Sutro Biopharma, Inc.'s owners and officers?
Sutro Biopharma, Inc.: business address in South San Francisco, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-09 | Coastlands Capital LP | 5.14% |
| Schedule 13G/A, 2026-08-14 | Point72 Asset Management, L.P. | 1.4% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 7.9% |
| Schedule 13G, 2026-07-30 | Blackrock, Inc. | 6.4% |
| Schedule 13G/A, 2026-05-15 | Kynam Capital Management, LP | 5.27% |
| Schedule 13G, 2026-05-15 | Srinivas Akkaraju | 6.4% |
| Schedule 13G/A, 2026-05-14 | Affinity Asset Advisors, LLC | 6.5% |
| Schedule 13G, 2026-05-01 | Point72 Asset Management, L.P. | 5.7% |
| Schedule 13G, 2026-04-21 | Perceptive Advisors LLC | 5.4% |
| Schedule 13G/A, 2026-04-21 | Millennium Management LLC | 1.3% |
| Schedule 13G, 2026-02-18 | Bvf Partners L P/Il | 7.6% |
| Schedule 13G/A, 2026-02-13 | Suvretta Capital Management, LLC | 0% |
Questions about who owns Sutro Biopharma, Inc.
Who owns Sutro Biopharma, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Sutro Biopharma, Inc.: Perceptive Advisors LLC (7.9%, Schedule 13G/A, filed 2026-08-14), Bvf Partners L P/Il (7.6%, Schedule 13G, filed 2026-02-18), Affinity Asset Advisors, LLC (6.5%, Schedule 13G/A, filed 2026-05-14), Blackrock, Inc. (6.4%, Schedule 13G, filed 2026-07-30) and Srinivas Akkaraju (6.4%, Schedule 13G, filed 2026-05-15); 2 more are listed above.
Who are the largest shareholders of Sutro Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Sutro Biopharma, Inc. on this page are Perceptive Advisors LLC (7.9%), Bvf Partners L P/Il (7.6%) and Affinity Asset Advisors, LLC (6.5%).
When did Perceptive Advisors LLC buy into Sutro Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G, filed 2026-04-21, reporting 5.4%; its latest, Schedule 13G/A filed 2026-08-14, reports 7.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Sutro Biopharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sutro Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sutro Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Sutro Biopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 409,056 shares (2.5% of shares outstanding), 292,531 held directly and 116,525 indirectly (Form 4, 2025-03-07).
- , the chief financial officer and secretary: 160,805 shares (0.97% of shares outstanding) (Form 4, 2025-05-19).
- , the chief people and comm. officer: 130,127 shares (0.78% of shares outstanding), 119,744 held directly and 10,383 indirectly (Form 4, 2025-05-05).
- , the chief medical officer: 97,452 shares (0.59% of shares outstanding) (Form 4, 2025-05-05).
- , the chief tech op officer: 53,686 shares (0.32% of shares outstanding) (Form 4, 2025-05-05).
Shares outstanding: 16,581,171 as of 2026-08-07, from the company's latest SEC cover page.
How much has Sutro Biopharma, Inc. raised?
No fundraising or offering filing from Sutro Biopharma, Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2025-09-29).
Keep reading
More on Sutro Biopharma, Inc. and the records around it.
Sutro Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Layoff notices Sep 2025
Companies that share a holder
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/sutro-biopharma